🔍 Concall Decoded

🎙 Management Tone Tracker Confident Specific → Stable 3 quarters analysed

Q2 2025

Confident Specific

Management used precise language such as 'progressing as expected', 'outstanding clinical results', 'solid progress', and provided specific patient numbers (140+ for thyroid, 40 for clamp, 140+ for catheter) and procedure times (5-8 minutes ablation). The tone is assured and data-driven.

Q3 2025

Confident Specific

Management uses phrases like 'very pleased', 'excited to announce', 'incredibly promising' and provides specific numbers: over 200 patients treated, 44 EU cardiac surgery patients, 150 360 catheter patients, 40% PRECISE BTN enrollment. They give clear timelines for milestones (Q1 enrollment completion, Q1 data release) and cite specific physician quotes and study names.

Q1 2026 latest

Confident Specific

Management repeatedly used strong language like "landmark", "inflection point", "outstanding", and "simply outstanding" to describe clinical results and milestones. They gave concrete numerical achievements (100% six-month efficacy, 96% one-year, 1.7% safety event rate) and tightened enrollment guidance from end of 2026 to early Q4 2026, projecting execution confidence.

Guidance Reliability Pending · <3Q data

Investor Lens

The investment thesis is stronger after this call. The company delivered a clear inflection point with landmark European feasibility data (100% six-month efficacy, 90% one-year freedom from AF) and accelerated the U.S. pivotal enrollment timeline to early Q4 2026, reducing time to market. The strategic realignment to focus resources on the highest-value AF catheter program, coupled with strong early U.S. site feedback and rapid enrollment, suggests execution momentum. The surgical clamp timeline was modestly pushed back, but that was flagged as a resource shift. Risks include dilution risk from the ATM program ($60M available) and reliance on positive pivotal data to validate durability in a broader U.S. population. Key things to watch next quarter: the pace of site activations and enrollment in NANOPULSE-AF, any partnership announcements, and updates on CE mark submission timing.

AI-generated concall tone analysis · Updated 2026-06-09 · Not investment advice

🎙 Management Tone Confident Specific → Stable 3 quarters Full tone analysis in Intelligence →

📊 MIXED Pulse Biosciences advances nsPFA platform, enrolls U.S. pivotal trial for AF catheter.

Revenue & Profitability

Total Q1 2026 revenue was $401,000, with cost of product revenue of $370,000. GAAP net loss was $18.6 million, compared to $16.8 million in the prior year period. Non-GAAP net loss was $16.4 million, compared to $11.4 million in the prior year period. Cash and cash equivalents totaled $68.3 million as of March 31, 2026, decreasing from $80.7 million at December 31, 2025. Cash used in operations was $14.6 million in Q1 2026.

Outlook

Management sees an enormous unmet need in atrial fibrillation, with a rapidly growing market. They highlight the potential migration of AF ablation procedures to ambulatory surgery centers (ASCs), where the efficiency and safety of nsPFA align well. The company believes that the time-saving advantage of its catheter could drive rapid adoption and expand procedural capacity. No headwinds were explicitly mentioned; the tone is optimistic about market demand.

Growth Drivers

The primary growth driver is the nPulse cardiac catheter for paroxysmal AF, with a U.S. pivotal trial (NANOPULSE-AF) that began enrollment in April 2026 and is expected to complete enrollment by early Q4 2026. The surgical ablation clamp (NANOCLAMP-AF) is also a growth lever, with enrollment expected to complete by end of H1 2027. The Vybrance percutaenous system is generating modest revenue ($400K in Q1) and expanding into thyroid microcarcinoma via a collaboration with MD Anderson. Partnerships with mapping providers and EP market leaders are actively being pursued.

Balance Sheet & CapEx

Not discussed as a separate line item in this earnings call. Cash used in operating activities was $14.6 million in Q1 2026, reflecting investment in clinical trials, product development, and market development. The company has a $200 million shelf registration in effect and an ATM program with approximately $60 million of availability.

Margins

Margin trajectory was not explicitly discussed. Total GAAP costs and expenses increased $1.6 million to $19.6 million in Q1 2026, driven by clinical program investments. Non-GAAP costs and expenses increased $4.7 million to $17.4 million. No specific gross margin or operating margin guidance was provided.

Key Risks

In the Q&A, an analyst raised the risk of potential degradation of durability statistics when moving from the European feasibility study to the U.S. pivotal trial due to sicker patient populations. Management downplayed this, citing similar paroxysmal AF definitions and endpoints. They also noted that the company's cash position and ATM program provide liquidity, but reliance on financing was implicitly acknowledged through the discussion of shelf registration and executive participation in the ATM program.

Generated by AI · Q1 2026 results · Not investment advice

✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter

🔍

🔎 See cross-company document search → ?

📞 Earnings Call Transcripts (5)

Q2 2026 Q2 2026 2026-08-06

Q2 2026 saw rapid clinical trial enrollment, strong physician enthusiasm, and expanded partnerships, with revenue of $434,000 and a strengthened cash position of $101.6 million. Key IDE studies are ahead of schedule, and capital raised supports continued clinical and market development.

Q1 2026 Q1 2026 2026-05-07

Q1 2026 marked a pivotal quarter with accelerated clinical progress, strong feasibility data, and a sharpened focus on the nPulse cardiac catheter program. Financials showed increased investment in clinical trials, with ample liquidity to fund operations through key milestones.

Q4 2025 Q4 2025 2026-02-19

Nanosecond PFA platform advanced with strong clinical results in cardiac and soft tissue ablation, including 96% one-year procedural success for AF and growing Vibrance revenues. Cash reserves of $80.7M support pivotal trials and market expansion, with FDA clearances targeted for 2027.

Q3 2025 Q3 2025 2025-11-05

Q3 2025 saw initial commercial revenues, strong clinical progress, and pivotal trial launches for soft tissue and cardiac ablation devices. Cash use increased with expanded trials, and positive early outcomes support further adoption and market expansion.

Q2 2025 Q2 2025 2025-08-12

Q2 2025 saw expanded clinical adoption and strong feasibility results for nsPFA devices, with costs rising due to organizational growth and clinical trial investments. Initial revenue from the Percutaneous Electrode is expected in H2 2025, and regulatory progress continues for cardiac devices.

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯

Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.

📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.